Aldebaran AI

We're building the future of commercial strategy in life sciences. Our team sits at the intersection of artificial intelligence and pharmaceutical commercialisation — specifically market access, pricing, and value demonstration across pharma, biotech, and gene therapy. If you've worked in this space, you know the reality. Pricing decisions that take months of manual modelling. Market access strategies are assembled from fragmented data across dozens of sources. Payer landscapes that shift faster than teams can track. The commercial side of life sciences is overdue for a fundamental shift in how work gets done. That's what we're here to change. We're currently in stealth mode, and intentionally so. What we're developing isn't an incremental improvement or another dashboard. Our founding team brings deep domain expertise from both sides of the table — years spent inside pharma commercial organisations and years spent building enterprise AI products. We started this company because we saw a gap between what AI can actually do today and what commercial teams are still doing manually. We'll have more to share soon. In the meantime, we're assembling a world-class team of people who believe that smarter tools lead to faster access, better pricing decisions, and ultimately, patients getting therapies sooner. If that mission resonates with you — whether as a future customer, collaborator, or team member — follow along. The best is ahead.